Korean J Dermatol.
2005 Jan;43(1):92-95.
Cutaneous Adverse Effects Associated with Iressa(R)(Gefitinib) Medication
- Affiliations
-
- 1Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. eslee@smc.samsung.co.kr
Abstract
- We report cutaneous adverse effects developed in three patients and are probably related to Iressa(R)(Gefitinib, ZD1839) medication. Iressa(R) is a new anti-cancer agent which acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. The three patients had all taken Iressa(R) for treatment of non-small cell lung cancer and came to our clinic with cutaneous adverse effects. All three patients had acneiform eruptions, and one of the patients also had periungal granulation lesions. Histopathologically, periadnexal inflammatory cellular infiltrations were seen in the acneiform lesions of the three patients and granulation-like tissue proliferations in periungal granulation lesions of the one patient.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients
- Leukocytoclastic Vasulitis Induced by Gefitinib
- Gefitinib-induced Paronychia Teated by Cyosurgery
- Paronychia during Iressa(R) Treatment in a Lung Cancer Patient
- A Case of Gefitinib (Iressa(R))-associated Tumor Lysis Syndrome in Adenocarcinoma of the Lung
